Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P24043: Variant p.Gly2633Ala

Laminin subunit alpha-2
Gene: LAMA2
Feedback?
Variant information Variant position: help 2633 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Glycine (G) to Alanine (A) at position 2633 (G2633A, p.Gly2633Ala). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from glycine (G) to small size and hydrophobic (A) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In MDC1A. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 2633 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 3122 The length of the canonical sequence.
Location on the sequence: help PEPNLFHDGREHSVHVERTR G IFTVQVDENRRYMQNLTVEQ The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         PEPNLFHDGREHSVHVERTRGIFTVQVDENRRYMQNLTVEQ

Mouse                         PEPNLFHDGREHSVHVERTRGIFTVQIDEDRRHMQNLTEEQ
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 23 – 3122 Laminin subunit alpha-2
Domain 2526 – 2710 Laminin G-like 3
Glycosylation 2648 – 2648 N-linked (GlcNAc...) asparagine



Literature citations
Genotype/phenotype analysis in Chinese laminin-alpha2 deficient congenital muscular dystrophy patients.
Xiong H.; Tan D.; Wang S.; Song S.; Yang H.; Gao K.; Liu A.; Jiao H.; Mao B.; Ding J.; Chang X.; Wang J.; Wu Y.; Yuan Y.; Jiang Y.; Zhang F.; Wu H.; Wu X.;
Clin. Genet. 87:233-243(2015)
Cited for: INVOLVEMENT IN MDC1A; VARIANTS MDC1A 95-GLN--ASN-3122 DEL; 110-TRP--ASN-3122 DEL; 121-TYR--ASN-3122 DEL; 273-ARG--ASN-3122 DEL; 435-ARG--ASN-3122 DEL; TYR-518; 659-SER--ASN-3122 DEL; 744-ARG--ASN-3122 DEL; MET-821; 986-TRP--ASN-3122 DEL; 1032-CYS--ASN-3122 DEL; 1095-ARG--ASN-3122 DEL; GLY-1311; 1319-ARG--ASN-3122 DEL; 1350-ARG--ASN-3122 DEL; 1826-ARG--ASN-3122 DEL; VAL-2172 DEL; 2383-ARG--ASN-3122 DEL; 2578-ARG--ASN-3122 DEL; 2604-ARG--ASN-3122 DEL; ALA-2633; 2641-GLU--ASN-3122 DEL AND 2755-SER--ASN-3122 DEL;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.